In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report), with a price target of $22.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Yi Chen has given his Buy rating due to a combination of factors including the progress in EyePoint Pharmaceuticals’ clinical trials and financial outlook. The company is advancing its Phase 3 trials, LUGANO and LUCIA, for the DURAVYU treatment in wet age-related macular degeneration (AMD), with significant patient enrollment expected to be completed by the second half of 2025. These trials are critical as they are global, randomized, and controlled, aiming to demonstrate non-inferiority to aflibercept, a standard treatment.
Additionally, EyePoint Pharmaceuticals reported promising results from its Phase 2 VERONA trial for diabetic macular edema (DME), where the DURAVYU treatment showed a substantial reduction in treatment burden and improvement in visual acuity and central subfield thickness. Financially, the company is in a strong position with a cash runway extending into 2027, providing stability and resources to continue its development programs. These factors contribute to the positive outlook and justify the Buy rating with a price target of $22.
In another report released on May 13, J.P. Morgan also maintained a Buy rating on the stock with a $26.00 price target.